Early Intravenous Gamma Globulin Retreatment for Refractory Kawasaki Disease

• Published in: Clinical pediatrics Vol. 42; no. 3; pp. 269 - 272
• Main Authors: Chiyonobu, Tomohiro, Yoshihara, Takao, Mori, Kanako, Ishida, Hiroyuki, Nishimura, Yasutaka, Yamamoto, Yasutoshi, Kamiya, Yasutaka, Kasubuchi, Yasuo
• Format: Journal Article
• Language: English
• Published: 708 Glen Cove Avenue, Glen Head, NY 11545 SAGE Publications 01.04.2003; Westminster; Sage Publications, Inc; Westminster Publications, Inc
• Subjects: Biological and medical sciences; Child; Child, Preschool; Children & youth; Disease; Disease management; Female; Humans; Immunoglobulins, Intravenous - therapeutic use; Immunomodulators; Infant; Japan; Male; Medical sciences; Mucocutaneous Lymph Node Syndrome - drug therapy; Pediatrics; Pharmacology. Drug treatments; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Secondary Prevention; Japan; Human; Kawasaki syndrome; Gamma globulin; Immunopathology; Prognosis; Treatment efficiency; Coronary artery; Cardiovascular disease; Autoimmune disease; Vascular disease; Refractory; Retreatment; Chemotherapy; Vasculitis; Treatment; Systemic disease; Child
• ISSN: 0009-9228; 1938-2707
• DOI: 10.1177/000992280304200311

Although optimal management of patients with refractory Kawasaki disease (patients who fail to become afebrile after the initial course of IVIG, or intravenous gamma-globulin) has not been established, some clinicians advocate retreatment with IVIG. Persistent fever, one of the most important risk factors for coronary artery lesion development, is important to control as early as possible to prevent CAL formation.